Latest news

• Final data shows CureVac’s COVID-19 vaccine is only 48% effective

  A final analysis of a phase 2b/3 study of CureVac’s COVID-19 vaccine candidate CVnCoV demonstrated 48% overall efficacy, only a slight improvement on the previously reported 47% efficacy.

• Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

  CureVac’s first-generation mRNA vaccine candidate CVnCoV is 47% effective at preventing COVID-19 of any severity, according to preliminary data from a phase 2/3 study evaluating the jab. ... Beyond CVnCoV, CureVac has partnered with GlaxoSmithKline (GSK

• CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

  Company is aiming to receive European approval in June. German biopharma company CureVac is readying for the rollout of its mRNA-based COVID-19 vaccine CVnCoV, which may receive approval in ... The potential approval of CVnCoV comes months after the

• Novartis agrees to help produce Roche’s repurposed COVID-19 drug

  In March, Novartis signed an initial manufacturing agreement with CureVac to help manufacture the latter’s mRNA-based COVID-19 vaccine candidate CVnCoV. ... Deliveries of the CVnCoV doses from Novartis’ Kundl, Austria manufacturing site are expected

• CureVac expands COVID-19 vaccine trial protocol to include variant specification

  Initially, the study aimed to evaluate safety, reactogenicity and immunogenicity of CvnCoV in adult participants. ... The EMA’s Committee for Medicinal Products for Human Use (CHMP) started its rolling review of CVnCoV in February.